206 related articles for article (PubMed ID: 30217767)
1. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary.
Huang Z; Lin L; McGoverin C; Liu H; Wang L; Zhou QT; Lu M; Wu C
Int J Pharm; 2018 Nov; 551(1-2):103-110. PubMed ID: 30217767
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
3. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
4. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
[TBL] [Abstract][Full Text] [Related]
5. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
Pornputtapitak W; El-Gendy N; Berkland C
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
[TBL] [Abstract][Full Text] [Related]
6. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
[TBL] [Abstract][Full Text] [Related]
7. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
[TBL] [Abstract][Full Text] [Related]
8. Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation.
Lin L; Quan G; Peng T; Huang Z; Singh V; Lu M; Wu C
Int J Pharm; 2017 Nov; 533(1):84-92. PubMed ID: 28903066
[TBL] [Abstract][Full Text] [Related]
9. Hot-melt extrusion for enhanced delivery of drug particles.
Miller DA; McConville JT; Yang W; Williams RO; McGinity JW
J Pharm Sci; 2007 Feb; 96(2):361-76. PubMed ID: 17075869
[TBL] [Abstract][Full Text] [Related]
10. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
11. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Pharm Res; 2012 Oct; 29(10):2845-59. PubMed ID: 22644590
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
[TBL] [Abstract][Full Text] [Related]
13. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
Lang B; Liu S; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
[TBL] [Abstract][Full Text] [Related]
14. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
15. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
[TBL] [Abstract][Full Text] [Related]
16. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
DiNunzio JC; Miller DA; Yang W; McGinity JW; Williams RO
Mol Pharm; 2008; 5(6):968-80. PubMed ID: 19434851
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.
Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J
Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397
[TBL] [Abstract][Full Text] [Related]
18. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption.
Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition.
Miller DA; DiNunzio JC; Yang W; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2008 Aug; 34(8):890-902. PubMed ID: 18608468
[TBL] [Abstract][Full Text] [Related]
20. Novel pectin-based nanoparticles prepared from nanoemulsion templates for improving in vitro dissolution and in vivo absorption of poorly water-soluble drug.
Burapapadh K; Takeuchi H; Sriamornsak P
Eur J Pharm Biopharm; 2012 Oct; 82(2):250-61. PubMed ID: 22885158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
